The Relationship between Lymphocyte Subsets and the Prognosis and Genomic Features of Lung Cancer: A Retrospective Study

Abstract

Background: It has been shown that the prognosis of malignant tumors was closely related to the composition and function of immune system, which was associated with genomic features. However, the prognostic value of peripheral T lymphocyte subsets and its relationship with genomic features in lung cancer has not been analyzed extensively. Therefore, this study was intended to evaluate the relationship between lymphocyte subsets and the prognosis and genomic features of lung cancer. Methods: 598 lung cancer patients with complete data were included in this study between 2011 and 2018. Kaplan-Meier method and Pearson analyses were conducted to study the prognostic value of CD3+, CD4+, CD8+ T lymphocytes and the rate of CD4/CD8. Results: Patients with EGFR mutation has lower mean percentage of CD8+ lymphocytes than patients with EGFR wild-type (24.71 versus 26.62, respectively, P =0.041). Patients with high CD3 had better OS than those with low (27 versus 14 months, P =0.002). Patients with higher CD4 and CD4/CD8 rate had longer OS than with lower (27 versus 12 months, P =0.002; 25 versus 9 months, P =0.008, respectively). Patients with high CD8 had poor PFS than low group (6 versus 11 months, P =0.009). There was a negative correlation between CD3+ and CD4+ cells and OS in smoking stage Ⅱ female lung cancer patients (PCC = 0.626, P <0.05; PCC = 0.534, P <0.05, respectively). In stage Ⅰ male lung cancer patients, CD8+T cell is negatively correlated with OS and PFS (PCC = 0.295, P <0.05; PCC = 0.280, P <0.05, respectively) Conclusions: Lung cancer patients with EGFR mutation had lower percentage of CD8+ lymphocytes. Lymphocyte subsets might be potential prognostic biomarkers of lung cancer, but they are affected by gender and tumor stage.

The Effect of Microwave Ablation Combined with Anti-PD-1 Monoclonal Antibody on T Cell Subsets and Long-Term Prognosis in Patients Suffering from Non-Small-Cell Lung Cancer

“…CD4+ T lymphocytes, as auxiliary T cells, can not only play a direct killing role on tumor cells but also have immune memory function, playing a secondary immune role. CD8+ T lymphocytes are cytotoxic T lymphocytes, which can negatively regulate tumor immune response and can be used to evaluate the patient's autoimmune function [ 13 , 14 ]. In the process of the development of NSCLC, apoptosis of tumor-specific T cells and PD-1-dependent and PD-1-independent mechanisms of mediation are closely related.…”

Machine learning‐based radiomics to distinguish pulmonary nodules between lung adenocarcinoma and tuberculosis

“…should be collected to assess the clinical usefulness of the prediction model. [34][35][36] In conclusion, radiomics analysis has great potential to differentiate LUAD from TB. Also, the ROI segmentation with or without the cavity region inside the nodule may exert no significant effect on the predictive performance.…”

“…Finally, more clinical information (e.g., lymphocytes, tumor biomarkers, etc.) should be collected to assess the clinical usefulness of the prediction model 34–36 …”

Analysis of risk factors for the early death of lymphocyte subsets in adult patients with secondary hemophagocytic lymphohistiocytosis

“…For example, in a prospective study of diffuse large B-cell lymphoma (DLBCL), researchers found that a decreased number of NK cells at diagnosis was signi cantly associated with shorter event-free survival (EFS) in DLBCL patients [21] . Another study reported that lung cancer patients in the low CD3 + group had shorter overall survival (OS) than those in the high CD3 + group [22] . In viral infections, a relationship between immune abnormalities and disease prognosis has also been found.…”